JP2021516057A5 - - Google Patents
Info
- Publication number
- JP2021516057A5 JP2021516057A5 JP2020546997A JP2020546997A JP2021516057A5 JP 2021516057 A5 JP2021516057 A5 JP 2021516057A5 JP 2020546997 A JP2020546997 A JP 2020546997A JP 2020546997 A JP2020546997 A JP 2020546997A JP 2021516057 A5 JP2021516057 A5 JP 2021516057A5
- Authority
- JP
- Japan
- Prior art keywords
- variable region
- chain variable
- seq
- polypeptide sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132024A JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US62/640,955 | 2018-03-09 | ||
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US62/721,044 | 2018-08-22 | ||
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| US62/786,598 | 2018-12-31 | ||
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132024A Division JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516057A JP2021516057A (ja) | 2021-07-01 |
| JP2021516057A5 true JP2021516057A5 (https=) | 2022-03-10 |
| JP7334177B2 JP7334177B2 (ja) | 2023-08-28 |
Family
ID=67846304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546997A Active JP7334177B2 (ja) | 2018-03-09 | 2019-03-05 | 抗ｃｄ７３抗体及びその使用 |
| JP2023132024A Active JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132024A Active JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (https=) |
| EP (1) | EP3762030A4 (https=) |
| JP (2) | JP7334177B2 (https=) |
| KR (2) | KR102804816B1 (https=) |
| CN (2) | CN111867628B (https=) |
| AU (1) | AU2019231172B2 (https=) |
| BR (1) | BR112020016049A2 (https=) |
| CA (1) | CA3090008A1 (https=) |
| IL (1) | IL276950B2 (https=) |
| MX (1) | MX2020009366A (https=) |
| SG (1) | SG11202007199XA (https=) |
| WO (1) | WO2019173291A1 (https=) |
| ZA (1) | ZA202004827B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| EP3861018A4 (en) | 2018-10-05 | 2022-10-26 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCY CYSTINosis AND WILSON'S DISEASE |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12116418B2 (en) | 2019-09-23 | 2024-10-15 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| MX2022003465A (es) | 2019-09-23 | 2022-06-16 | Univ Pennsylvania | Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana. |
| CA3161717A1 (en) * | 2019-11-15 | 2021-05-20 | Dana LORD | Biparatopic cd73 antibodies |
| EP4061420A1 (en) * | 2019-11-20 | 2022-09-28 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| PE20221409A1 (es) * | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| JP2023519969A (ja) | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | リソソーム蓄積症に関するプロテオミクススクリーニング |
| US12523662B2 (en) | 2020-04-02 | 2026-01-13 | Seattle Children's Hospital | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| US20230159655A1 (en) * | 2020-04-22 | 2023-05-25 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| US20240218074A1 (en) * | 2020-08-17 | 2024-07-04 | Akeso Biopharma, Inc. | Anti-cd73 antibody and use thereof |
| CN120590533A (zh) * | 2020-10-23 | 2025-09-05 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| CN114456268B (zh) * | 2020-11-09 | 2023-08-18 | 江苏中新医药有限公司 | 抗胞外-5’-核苷酸酶的抗体序列 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| TW202241441A (zh) | 2020-12-29 | 2022-11-01 | 美商英塞特公司 | 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法 |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| US20240174763A1 (en) * | 2021-02-24 | 2024-05-30 | Novoprotein Scientific Inc. | Anti-human cd73 antibody and use thereof |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| WO2023023354A2 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5382692B2 (ja) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| MA39986A (fr) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| EP3204417B1 (en) | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CN114805575B (zh) * | 2015-12-09 | 2024-07-23 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
-
2019
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 IL IL276950A patent/IL276950B2/en unknown
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516057A5 (https=) | ||
| KR102503084B1 (ko) | 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도 | |
| JP2021526022A5 (https=) | ||
| JP2021517459A5 (https=) | ||
| JP2022509930A (ja) | 抗ｃｄ７３抗体、その抗原結合フラグメントおよびそれらの使用 | |
| JP2021514664A5 (https=) | ||
| CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2024531409A5 (https=) | ||
| JP2012012402A5 (https=) | ||
| JP2013539369A5 (https=) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2021528047A5 (https=) | ||
| CN112513088B (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| AU2016319433A1 (en) | Anti-EphA4 antibody | |
| JP2021512652A5 (https=) | ||
| TW201904998A (zh) | 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途 | |
| EP3016982A1 (en) | Antibodies to toso | |
| CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| JP2024516621A5 (https=) | ||
| CA3141673A1 (en) | Anti-hepatitis b virus antibodies and use thereof | |
| CN118591554A (zh) | 抗人cxcl1抗体 | |
| CN109957011B (zh) | 抗h7n9全人源单克隆抗体6e9及其制法与应用 | |
| CN120040594B (zh) | 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用 |